NGS-driven molecular testing in HER2-mutant NSCLC guides oncology care, highlighting new HER2-targeted TKIs and ADCs, CNS activity, toxicity tradeoffs, and trials.
Evolving Approaches in HER2-Mutant Non–Small Cell Lung Cancer: Emerging Evidence and Practical Considerations
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
5